12d agoCNBCBEARISH 34Analyst
Archived explainer. For the current picture see today's AMGN page.
Why Is AMGEN INC (AMGN) Stock Moving Today?
By the Top Tier Newswire AI Desk · August 31, 2026 at 11:59 PM ET · reviewed against 7 wire stories
AMGEN INC (AMGN) is drawing unusual attention today. Our newswire has captured 7 stories on AMGN across 6 sources in the last 36 hours, with AI sentiment reading mixed (avg 57/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
AMGN stock is moving higher by 1.4% in early trading as new data from its Repatha drug shows a 20% reduction in death risk for high-risk patients in a Phase 3 trial. The study, known as VESALIUS-CV, involved over 12,000 patients and demonstrated a 36% reduction in heart attack risk. These results, reported by Amgen, are expected to bolster confidence in the drug’s long-term value and reinforce its position in the cardiovascular market.
What Happened
Amgen released detailed results from the VESALIUS-CV trial, confirming that Repatha significantly reduces mortality in patients at high risk for a first heart attack or stroke. The findings were highlighted in multiple reports over the past 36 hours, with specific emphasis on the drug’s performance after 1.5 years of treatment and a median follow-up of 4.6 years. The data supports the drug’s role in primary prevention, a market segment that could expand its commercial potential. In addition, Amgen and AstraZeneca reported positive Phase III results for TEZSPIRE in treating eosinophilic esophagitis, further reinforcing the company’s recent momentum in clinical development.
What The Data Shows
AMGN opened at $432.00 and reached an intraday high of $433.06 before settling at $433.00. The stock is trading at 0.7 times its 3-month average volume, indicating moderate participation. The stock has outperformed the broader market over the past year and currently trades within its 52-week range of $269.77 to $447.03. Over the last 8 sessions, the stock has declined slightly by 0.5% from $433.73 to $431.65. Recent insider transactions include three sales totaling $4.1 million, with no insider purchases reported in the last 90 days.
What To Watch
Investors should monitor Amgen’s upcoming dividend payment of $2.52 per share, set for ex/effective on August 21, 2026. The company’s continued progress in late-stage trials and its strong financials, including a 23% net margin and $8.1 billion in free cash flow in 2025, will remain key focus areas for the stock’s performance.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
AMGN by the numbers
7 sessions: -0.48%Coverage: 7 stories / 6 sourcesAI sentiment: 57/100 (mixed)Mkt cap: $233.8BP/E: 26.952w: $269.77 to $447.03
The headlines behind the move
13d agoSeeking AlphaNEUTRAL 47General
4 stocks to watch on Monday: AMGN, LLY, ARM, and MSTR
Stock futures dip on Middle East tensions: watch Arm CEO pay vote, Lilly’s Merida deal, Amgen Repatha data, and Strategy’s Bitcoin buy.
13d agoBarchartBULLISH 56Analyst
How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers
AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.
13d agoThe FlyBULLISH 67Product/PR
Amgen Repatha reduces risk of death in high-risk adults for first heart attack
13d agoSeeking AlphaBULLISH 73Product/PR
Amgen's Repatha cuts death risk by 20% in heart study
Amgen’s Phase 3 VESALIUS-CV data show Repatha cut death risk 20% in high-risk adults on statins—see ESC 2026 findings and key takeaways.
13d agoStockTitanBULLISH 67Product/PR
AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
In more than 12,000 patients, the reduction in deaths began after about 1.5 years; median follow-up was 4.6 years, and heart attack risk fell 36%.
14d agoYahoo FinanceBULLISH 57Analyst
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on AMGN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier AMGN move explainers: 2026-09-09 · 2026-09-08 · 2026-08-31